Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PATHFINDER: A Pragmatic, Active-comparator, Parallel-group, Randomized Trial to Evaluate the Optimal First-line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

NCT05928039 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT05928039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05928039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PATHFINDER: A Pragmatic, Active-comparator, Parallel-group, Randomized Trial to Evaluate the Optimal First-line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
Lead sponsor
University of Calgary
Phase
Phase 4
Overall status
Recruiting
Start date
October 25, 2023
Completion date
December 31, 2028
Enrollment
297 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease